Carl-Magnus Högerkorp holds a PhD in immunology from Lund University, as well as an MBA from EFL/Lund school of Economics and Management. He brings long and broad experience from pharma and biotech companies, both internationally and nationally. During his career, Dr Högerkorp has for example worked with research and development projects within infectious disease, immuno oncology, regenerative medicine, inflammation and autoimmune diseases. Further, he has held senior positions in several companies such as CEO for Edvince, Canimguide Therapeutics and ImModulate Pharma and CSO at Xintela, where he took part in the introduction of the company on Nasdaq First North Growth Market.